Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax, Inc. (Nasdaq: NVAX) announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™, a protein-based COVID-19 vaccine, for adolescents aged 12 to 17. This approval allows Nuvaxovid to be used as a primary series and booster for older populations. The decision is based on the Phase 3 PREVENT-19 trial, which showed an 80% clinical efficacy during the Delta variant's prevalence. The vaccine was well-tolerated, with low serious adverse events. Nuvaxovid is already authorized in several countries for this age group, enhancing global vaccination efforts.
Novavax announced that its COVID-19 vaccine, Nuvaxovid™, has received expanded provisional approval from New Zealand's Medsafe. This approval allows Nuvaxovid to be used as both a first and second booster dose for adults aged 18 and older, regardless of the primary vaccine received. As New Zealand faces a surge of COVID-19 cases, Novavax emphasizes its vaccine’s broad immune response to circulating variants. The approval is supported by data from several Phase 2 trials, demonstrating strong immune responses post-booster. Nuvaxovid is also provisionally registered in Australia and approved in Japan.
Novavax has submitted an application to the U.S. FDA for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted, as a booster for adults 18 and older. If approved, it would be the first protein-based booster available, complementing immunity from other vaccines. Data from the Phase 3 PREVENT-19 trial indicates that the booster dose generates robust antibody responses. The vaccine aims to enhance immunity against various COVID-19 variants and has previously received EUA for primary vaccination. Robust safety and immune response data back the application.
Novavax, Inc. (Nasdaq: NVAX) and SK bioscience have received approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid, the first protein-based COVID-19 vaccine for adolescents aged 12-17 in South Korea. This approval follows successful data from the Phase 3 PREVENT-19 trial, showing Nuvaxovid achieved 80% clinical efficacy against COVID-19 during the Delta variant surge. The vaccine has also received authorizations in countries like India and the European Union and has demonstrated a favorable safety profile.
Novavax, Inc. (Nasdaq: NVAX) will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum on August 18, 2022, from 11:00 to 11:50 a.m. EDT. The discussion will focus on NVX-CoV2373, Novavax's recombinant nanoparticle protein-based COVID-19 vaccine candidate. Key participants include Filip Dubovsky, M.D., and John J. Trizzino. Novavax's COVID-19 vaccine has received multiple global authorizations and is under review for additional populations. The company is also evaluating a combination vaccine candidate and new Omicron strain-based vaccines.
Novavax (NVAX) has received FDA Emergency Use Authorization for NVX-CoV2373, becoming the first protein-based COVID-19 vaccine authorized for adults in the U.S. The company reported a total revenue of $186 million in Q2 2022, a decline from $298 million the previous year, with adjusted revenue guidance set between $2 billion and $2.3 billion for the year. Despite delivering over 73 million doses globally, Novavax faced a net loss of $510 million. The company continues to progress its variant program, with further clinical data expected.
Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial for the COVID-19 vaccine (NVX-CoV2373) targeting children aged six months to 11 years. The trial will evaluate safety, immunogenicity, and efficacy of two doses, followed by a booster. Enrollment will include 3,600 participants from several countries, with initial results expected in Q1 2023. CEO Stanley C. Erck expressed optimism about expanding vaccine access to all age groups in the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) will report its Q2 2022 financial results and operational highlights on August 8, 2022, after U.S. market close. A conference call is scheduled for 4:30 p.m. EDT, and participants are encouraged to join 10 minutes early. The event will be available for replay starting at 7:30 p.m. EDT on the same day until August 15, 2022. Novavax emphasizes its commitment to developing vaccines for serious infectious diseases, including its COVID-19 vaccine, NVX-CoV2373, now authorized globally.
Novavax, Inc. (Nasdaq: NVAX) announced that its COVID-19 vaccine, Nuvaxovid™, received expanded approval from Japan's Ministry of Health for use in adolescents aged 12 to 17. This approval is based on data from a pivotal Phase 3 trial demonstrating 80% clinical efficacy among 2,247 participants, particularly during the Delta variant surge. Novavax has partnered with Takeda for manufacturing and distribution in Japan. Nuvaxovid has also been authorized in multiple countries, including the European Union and India, and is under review in additional markets.
Novavax (Nasdaq: NVAX) announced that the Australian Therapeutic Goods Agency has granted provisional registration for its COVID-19 vaccine, Nuvaxovid™, for adolescents aged 12 to 17. This decision aims to address rising COVID-19 cases in Australia, especially as schools reopen. Based on the pediatric expansion of the PREVENT-19 clinical trial, Nuvaxovid demonstrated an overall efficacy of 80%, with a favorable safety profile. The vaccine is already conditionally authorized in the European Union and received emergency use authorization in India. This marks an important step in expanding vaccination access.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
